Assessment of plasma acylcarnitines before and after weight loss in obese subjects by Schooneman, Marieke G et al.
                          Schooneman, M. G., Napolitano, A., Houten, S. M., Ambler, G. K.,
Murgatroyd, P. R., Miller, S. R., ... Soeters, M. R. (2016). Assessment of
plasma acylcarnitines before and after weight loss in obese subjects. Archives
of Biochemistry and Biophysics, 606, 73-80.
https://doi.org/10.1016/j.abb.2016.07.013
Peer reviewed version
License (if available):
CC BY-NC-ND
Link to published version (if available):
10.1016/j.abb.2016.07.013
Link to publication record in Explore Bristol Research
PDF-document
This is the author accepted manuscript (AAM). The final published version (version of record) is available online
via Elsevier at https://www.sciencedirect.com/science/article/pii/S0003986116302454?via%3Dihub. Please refer
to any applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
  
Assessment of plasma acylcarnitines before and after weight loss in obese subjects. 
 
M.G. Schooneman*1,6, A. Napolitano3, S.M. Houten5, G. Ambler2, P.R. Murgatroyd4, S. Miller3, C.Y. 
Tan2, S. Virtue2, A. Vidal-Puig2, D.J. Nunez3 and M.R. Soeters*1,2 
 
1Department of Endocrinology and Metabolism, Academic Medical Center, Amsterdam, 
University of Amsterdam, The Netherlands 
2Institute of Metabolic Science, Metabolic Research Laboratories, Cambridge University Hospital 
NHS Trust, Cambridge, UK 
3GlaxoSmithKline Research and Development, Research Triangle Park, North Carolina, 27709 
USA 
4Wellcome Trust Clinical Research Facility, Cambridge University Hospital NHS Trust, 
Cambridge, UK 
5Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, 
New York, USA 
6Department of Clinical Chemistry, Laboratory Genetic Metabolic Diseases, Academic Medical 
Center, University of Amsterdam, The Netherlands 
 
Word Count abstract: 217 
Word Count: 3911 
References: 40 
Figures: 10 
Disclosure statement: The authors have nothing to disclose. 
Funding statement: This study was sponsored by GlaxoSmithKline and a MRC program grant 
from the NIHR Cambridge Biomedical 
Key words: acylcarnitines; insulin resistance; fatty acid oxidation; weight loss 
* Corresponding Author: M.R. Soeters/M.G. Schooneman 
  
Abstract 
Acylcarnitines, fatty acid oxidation (FAO) intermediates, have been implicated in diet-induced 
insulin resistance and type 2 diabetes mellitus. Moreover plasma acylcarnitines have been 
associated with clinical parameters related to glucose metabolism, such as fasting glucose levels 
and HbA1c. We investigated plasma acylcarnitines in relation to energy metabolism (including 
energy expenditure (EE)) and insulin sensitivity measurements in 60 obese subjects before and 
after a 12 week weight loss intervention. Since the acylcarnitine profile reflects FAO at the 
mitochondrial level, we expected plasma acylcarnitines to correlate with energy expenditure, 
insulin sensitivity and other clinical parameters before and during a weight loss intervention. In 
contrast, despite the amelioration of HOMA-IR, plasma acylcarnitines levels increased during 
weight loss. This is most probably attributable to higher lipolysis and lipid oxidation rates due to 
the caloric deficit and not by mitochondrial overload and incomplete FAO, as insulin signalling 
was not impaired. HOMA-IR, energy expenditure and respiratory exchange ratio were not 
related to plasma acylcarnitines. However a strong correlation between NEFA and several 
acylcarnitines was found at baseline and during the weight loss intervention, again potentially 
reflecting lipolysis. Our data show that acylcarnitines do not correlate with clinical parameters 
of glucose metabolism during weight loss, questioning the role of acylcarnitines in the etiology of 
insulin resistance and subsequent type 2 diabetes mellitus. 
  
Introduction 
With the increased incidence of obesity and type 2 diabetes mellitus, many studies focus on the 
interaction between lipid and glucose metabolism, and the relationship to insulin resistance. The 
concept of lipotoxicity has been proposed as a mechanism by which increased lipid levels 
interfere with insulin signalling and eventually lead to hyperglycemia. However, the exact 
mechanisms and the individual lipids that induce insulin resistance have not been characterised 
definitively. From a cellular point of view, lipotoxicity is thought to occur on a cytosolic level via 
lipid overload (e.g. increased levels of ceramides, gangliosides or diacylglycerol) (1-4). Reduced 
mitochondrial content or capacity may result in elevated intracellular lipids (3, 5). Alternatively, 
increased fatty acid oxidation (FAO) rates that are not followed by an increase in tricarboxylic 
acid cycle (TCA) activity have been proposed to induce insulin resistance via accumulation of 
different mitochondrial metabolites such as acylcarnitines (1, 6, 7). This incomplete FAO is 
suggested to be manifested by altered plasma acylcarnitine profiles, mainly increased levels of 
long chain acylcarnitines (1, 7, 8).  
Acylcarnitines are fatty acids esterified to carnitine. They are synthetized by the outer 
membrane enzyme carnitine palmitoyl tranferase 1 (CPT1) to enable transmitochondrial 
membrane transport of long-chain acyl-CoAs. Inside the mitochondrion, carnitine is exchanged 
for CoA via the inner mitochondrial membrane enzyme CPT2. Here the released acyl-CoA can be 
further oxidized via beta-oxidation, in which the acyl-CoA is shortened by one acetyl-CoA unit in 
every round. CPT-2 can convert acyl-CoAs into acylcarnitines again, which can be shuttled back 
into the cytosol and exported to the plasma compartment, ultimately contributing to the typical 
circulating profile of acylcarnitines (9). Consequently, acylcarnitines are excellent indicators of 
altered FAO as demonstrated by conditions in which lipid oxidation rates are elevated or when 
lipid oxidation is impaired (e.g. short-term fasting and FAO disorders). More recently, 
metabolomic studies have shown that acylcarnitines may be implicated in insulin resistance (7, 
8, 10), as elevated acylcarnitine levels are found in both rodent models of dietary insulin 
resistance (7) and in obese, insulin resistant humans (8). Also several acylcarnitine species 
  
correlate moderately with clinical markers such as BMI, plasma glucose levels and insulin 
sensitivity in humans with obesity and type 2 diabetes mellitus (8, 10). 
Here we report on plasma acylcarnitine concentrations before and during weight loss in obese 
human subjects. Based on the association of long- and short-chain acylcarnitines with type 2 
diabetes mellitus, we hypothesized that these acylcarnitine levels would decrease with 
concomitant improvements in insulin sensitivity. In contrast, we observed that decreased body 
weight and improvements in insulin sensitivity were accompanied by increased plasma 
acylcarnitine levels. Moreover, we found that plasma acylcarnitines correlate strongly with 
plasma non-esterified fatty acids (NEFA). 
 
Research design and methods  
 
Design of the study 
Sixty obese subjects were recruited to take part in an outpatient study for weight loss prediction 
that has been reported elsewhere (11). In brief, subjects aged 20-55 years and BMI 30-40 kg/m2 
were included. Exclusion criteria were as follows: type 2 diabetes mellitus, history of childhood 
obesity and previous bariatric surgery. After giving informed consent, subjects were randomized 
to one of three 12-week weight loss interventions: (1) diet (-600 kcal/day) alone, (2) the same 
diet with moderate exercise (~10% of daily expenditure), and (3) the same diet with the 
centrally acting serotonin-norepinephrine reuptake inhibitor, sibutramine, which was approved 
for weight loss at the time this study was conducted. During the study, subjects visited the 
clinical unit at 0, 4 and 12 weeks at 07:00 hours a.m. after an overnight fast for the measurement 
of body weight, anthropometry, indirect calorimetry and blood sampling (e.g. plasma 
acylcarnitine, glucose, non-esterified fatty acids and insulin levels). The study was approved by 
the protocol review panel of GlaxoSmithKline, the Cambridge Local Research Ethics Committee 
(08/H0308/10) and the Wellcome Trust Clinical Research Facility Scientific Advisory Board. 
Subjects gave written informed consent before participation. 
  
 
Body weight measurement and anthropometry by DXA 
Body weight was measured in light clothing. Body composition was analysed by DXA (GE Lunar 
Prodigy, software version 12.2 (GE Healthcare, Madison, WI) and quantitative magnetic 
resonance (Echo MRI-AH; Echo Medical Systems, Houston TX). Indirect calorimetry was 
performed using a ventilated canopy calorimetry instrument (GEM Nutrition, Daresbury, UK) 
with the subject lying supine for 20 minutes before the measurement. Expired gas samples were 
analyzed every 30 seconds for 20 minutes. Gas exchanges of O2 and CO2 were computed to 
calculate respiratory exchange ratio (RER) and energy expenditure (EE; kJ/min using the 
following formula: 15.9131 x O2 consumption + 5.2069 x CO2 production x 0.9950) (12). 
 
Laboratory analyses 
For plasma acylcarnitine analysis, 50 µl of plasma was mixed with 100 µl of internal standard 
mixture (50 µl of 5 µM [3,3,3-2H3]C3-carnitine and 2 µM [6,6,6-2H3]C6-, [8,8,8-2H3]C8-, [10,10,10-2H3]C10- and 
[16,16,16-2H3]C16-carnitine in acetonitrile (ACN), and 50 µL of 26 µM [methyl-2H3]-L-carnitine in 
10% ACN) [38]. The plasma samples were deproteinized by addition of 500 µL ACN followed by 
vortex mixing. Next, samples were centrifuged for 10 minutes at 4°C at 20.000 g. The 
supernatant was transferred into 4 mL glass vials and evaporated under a stream of nitrogen at 
40°C. After evaporation, 100 µL butylation reagent (4:1 mixture of 1-butanol and acetylchloride) 
was added and incubated for 15 minutes at 60°C. Again evaporation was performed at 40°C. The 
residue was dissolved in 100 µL ACN, vortex mixed and transferred to Gilson vials for tandem 
mass spectrometric analysis (Waters/Micromass Quattro Premier XE). Acylcarnitine 
measurements were processed with Masslynx software version 4.1. 
Acylcarnitines are depicted as C followed by chain length and degree of saturation. The 
acylcarnitines which we analysed were as follows: Free carnitine (C0), acetylcarnitine (C2; 
derived from both lipid and carbohydrate oxidation (CHO)), hydroxybutyrylcarnitine (C4OH; the 
sum of the L and D stereoisomers derived from FAO and ketone bodies respectively (13)), 
  
decanoylcarnitine and tetradecenoylcarnitine (C10 and C14:1 respectively; intermediates that 
are only produced by FAO and thus indicative of FAO rate) and finally palmitoylcarnitine and 
oleoylcarnitine (C16 and C18:1 respectively; intermediates that originate from the diet). 
Glucose was measured using a hexokinase assay. Insulin was measured using a fluorometric 
autoDELFIA immunoassay. Plasma free fatty acids were analysed with an NEFA-HR(2) in vitro 
enzymatic colorimetric method (Wako Diagnostics, Richmond VA). 
 
Statistical analysis 
For differences between subgroups at baseline, one-way ANOVA with Bonferroni correction was 
performed. To determine if plasma acylcarnitine levels at baseline predicted clinical parameters, 
Pearson correlation analyses were performed followed by Bonferroni correction. In case of 
significant results, multiple regression analysis was done to establish which acylcarnitine had 
the greatest effect on a single clinical parameter. Differences between days 0, 28 and 84 for 
whole group and within subgroup data were analysed using repetitive ANOVA analysis with 
Bonferroni correction. Statistical analysis was done with SPSS statistical software program 
version 20.0. Data are depicted as mean and standard deviation. 
To analyse if changes in plasma acylcarnitine levels over time coincided with changes in clinical 
parameters, we used a Bayesian hierarchical model with fixed and random effects. Individual 
variables were modelled by linear regression over time. For instance, changes in weight were 
modelled as: . Here  is the weight of subject i at time t,  is the 
mean weight of subject i,  is the rate of change of the subject's weight over time t, and  is 
a zero mean Gaussian error term: . Similarly, each of the acylcarnitines of interest 
was modelled for each individual patient by linear regression ( , where C 
is any acylcarnitine of interest). To analyse the correlation over time between individual clinical 
parameters (for example, weight) and acylcarnitines, we modeled  as a linear regression over 
 :  where  is again a zero mean Gaussian error term. We then applied 
Gibbs sampling to simulate from the posterior distribution using standard software (Just 
  
Another Gibbs Sampler (JAGS, version 3.4.0, http://mcmc-jags.sourceforge.net/)). We used a 
single Markov chain with a burn-in of 100000 sweeps and then output the values α and β for a 
further 1000000 sweeps. The proportion of sweeps when β is greater than zero is then the 
posterior probability that variables are positively correlated, and the proportion of sweeps 
when β < 0 is the posterior probability that variables are negatively correlated. This procedure 
was repeated for all clinical parameters and acylcarnitines of interest followed by the 
Bonferroni-Holm method to allow for multiple testing (14). 
 
Results 
Whole group clinical data and plasma acylcarnitines at baseline (day 0) 
Table 1 shows the clinical characteristics of the subjects at day 0 of the study. More women were 
included then men, and a substantial part of the subjects showed slight impaired fasting plasma 
glucose levels (FPG) (15), as well as an elevated homeostatic model assessment of insulin 
resistance (HOMA-IR) index (16). Table 1 additionally shows the levels of the plasma 
acylcarnitine, of which plasma C16- and C18:1-carnitine levels of our obese subjects were below 
clinical laboratory reference values. The levels of other acylcarnitines detected within the 
spectrum are given in the online supplemental data (Supplemental table 1). 
To detect relationships between plasma acylcarnitines and clinical parameters at baseline, we 
performed Spearman correlation analyses. Our analysis showed that plasma NEFA correlated 
strongly with C2, C4OH, C14:1, C16 and C18:1-carnitine (Table 2 and figure 1). No other 
correlations were found (Supplemental table 2). Multiple regression identified C14:1 and C16-
carnitine as contributors to the variation in plasma NEFA (Table 3). When C4OH-carnitine was 
omitted from the regression analysis (since this is an acylcarnitine that emerges predominantly 
during starvation (13)), only C16-carnitine remained significant.  
 
Whole group clinical data and plasma acylcarnitines during the weight loss intervention 
  
Figure 2 shows the effects of the weight loss interventions for the whole group, irrespective of 
the randomized treatment allocation. Overall, weight decreased significantly between days 0 and 
84 (~4.5 kg). As a consequence, BMI decreased between 0 and 28 days, with no additional 
significant reduction between days 28 and 84. HOMA-IR, FPG and plasma insulin levels 
improved significantly between days 0 and 28, with no further improvement hereafter (figure 
2). Plasma NEFA levels were unaffected by the intervention. Body composition analysis revealed 
that fat mass continued to decrease during the entire weight loss intervention period although 
this effect was most pronounced during the first 28 days. Lean body mass decreased 
significantly (~0.6 kg) until 28 days only (figure 2). Substrate oxidation measurements by 
indirect calorimetry showed that both EE and RER were significantly lower after 28 days of 
treatment, with no further reduction afterwards (figure 2). FAO rates did not change upon 
weight loss. However protein oxidation rates and CHO rates both significantly decreased after 28 
days and remained at this level at 84 days (Supplemental figure 1). The decrease in protein 
oxidation was minor, therefore the decrease in energy expenditure mainly resulted from lower 
carbohydrate oxidation. Overall clinical improvements due to the weight loss intervention were 
greatest in the first 28 days, with no further improvement at 84 days. 
Whole group plasma acylcarnitine levels for days 0, 28 and 84 are shown in figure 3. The weight 
loss intervention resulted in an increase in free carnitine levels after 84 days. C2-carnitine and 
C4OH-carnitine were higher after 28 days with no further increase at 84 days. C14:1- and C18:1-
carnitine showed a similar pattern over time with an initial increase in plasma levels after 28 
days, followed by a decrease at 84 days, although at this point these acylcarnitine levels were 
still higher compared with day 0. C16-carnitine was significantly higher after 28 days followed 
again by a decrease to baseline levels (figure 3). 
We used a Bayesian hierarchical model to investigate whether changes in plasma acylcarnitine 
levels over time correlated with changes in weight, fat mass, lean mass, HOMA-IR, FPG, NEFA, 
RER and EE. We found that the increase over time in C4OH-, C16- and C18:1-carnitine correlated 
significantly with a reduction in both total and lean body weight over time (Supplemental table 2 
  
and supplemental figure 2). Additionally over time NEFA levels correlated positively with the 
level of C16-carnitine (Supplemental table 2 and supplemental figure 2). We found no significant 
correlations for the other clinical parameters (data not shown). 
 
Subgroup clinical data and plasma acylcarnitines at baseline (day 0) 
Table 1 shows the demographic data at baseline for the subgroups. Although in general there 
were no differences between the groups, there were a few exceptions that were primarily driven 
by the exercise and sibutramine group. Plasma glucose and RER were both higher in the 
sibutramine group when compared to the exercise group. A difference in RER was also found for 
FAO and CHO rates (Table 1). Plasma NEFA levels were lower in the exercise group when 
compared to the other two groups (Table 1). 
 
Subgroup clinical data and plasma acylcarnitines during the weight loss intervention 
The sibutramine group showed continued weight loss up to day 84 in contrast to the other two 
groups that only showed significant weight loss at day 28, but then remained weight stable up to 
day 84. The sibutramine group had a significant reduction in HOMA-IR at day 28, after which the 
levels plateaued in contrast to the exercise and placebo groups where HOMA-IR did not change 
during the study. Plasma NEFA did not change in any of the three groups. In the exercise and 
placebo groups, RER was not affected by the weight loss intervention, but the sibutramine group 
had a lower RER after 28 days that remained stable thereafter. 
Plasma acylcarnitine levels showed differential changes during the weight loss intervention. 
Overall the greatest effect was seen in the sibutramine group and a modest effect was seen for 
the exercise group. In the placebo group, C0-carnitine did not change, whereas the exercise 
group showed a modest increase at day 84 compared to day 28. In the sibutramine group, C0-
carnitine increased steadily during the intervention becoming significant at day 84. In contrast 
to the placebo and exercise group, C2- and C4OH-carnitine levels in the sibutramine group 
showed an increase at 28 days and remained high at 84 days. In the placebo and sibutramine 
  
group, C10- and C14:1-carnitine initially increased at day 28 but not in the exercise group. C16- 
and C18:1-carnitine were higher at day 28 compared to day 0 in all groups, with the exception of 
C16-carnitine in the exercise group. At day 84, C10- and C18:1-carnitine were significantly 
decreased again in the placebo group compared to day 28. 
We repeated the Bayesian hierarchical modeling to determine if changes in plasma acylcarnitine 
levels overtime correlated with changes in clinical parameters and found that the change in 
plasma C4OH- and C18:1-carnitine remained significantly correlated with weight change in the 
sibutramine group, but not in the other groups (data not shown). 
  
  
Discussion  
It has been suggested that acylcarnitines play a role in insulin resistance (1, 17). In this study we 
have shown in obese humans that upon weight loss the improvement in insulin sensitivity was 
accompanied by a significant increase in acylcarnitine levels. Additionally the plasma levels of 
acylcarnitines increased and acylcarnitines correlated positively with NEFA at baseline and over 
time.  
Several studies have reported that increased plasma acylcarnitine levels associate with obesity 
and insulin resistance (7, 8, 10, 18). Adams et al reported that C2-carnitine, derived from both 
lipid and carbohydrate oxidation, correlated positively with HbA1c in diabetic subjects (10). 
Mihalik et al showed multiple correlations of short and longer chain acylcarnitines with glucose 
metabolism (8). Although they did not report C2-carnitine values, they found strong correlations 
with C4-dicarboxylcarnitine (C4-DC-CN) with fasting plasma glucose levels and HbA1c. In our 
study, plasma NEFA correlated positively with plasma C16-carnitine and other species, namely 
C2-, C14:1- and C18:1-carnitine. With respect to this strong correlation of acylcarnitines with 
plasma NEFA, which are known to induce insulin resistance, the overall absence of correlations 
between acylcarnitines and markers of insulin sensitivity is remarkable (19, 20). Since plasma 
NEFA are indicative of lipolysis, acylcarnitines in the plasma may reflect white adipose tissue 
(WAT) breakdown (21). As a result, the NEFA released from WAT could drive FAO rates 
generating acylcarnitines.  
The origin of the different acylcarnitines that correlate with plasma NEFA is intriguing as well. 
As discussed above, C2-carnitine can be derived from both lipid and carbohydrate oxidation and 
our observation of a correlation between C2-carnitine and plasma NEFA suggests that lipid is the 
main source in our subjects (22, 23). C16- and C18:1-carnitine are derived from palmitate and 
oleate, which are the main human dietary fatty acids. Their correlation with plasma NEFA may 
support lipolysis as a responsible mechanism, since these dietary fatty acids are stored in WAT. 
Finally, C14:1-carnitine is an interesting acylcarnitine since it is only produced after two cycles 
of beta-oxidation of C18:1-CoA (24). Therefore C14:1-carnitine  is a good marker of FAO. It 
  
remains unclear what the tissue origin of this acylcarnitine is, but as FAO also takes place in 
WAT, C14:1-carnitine could still be derived from WAT (25, 26). Alternatively, plasma NEFA may 
reflect the load of fatty acids in general, thereby correlating with the most metabolically relevant 
acylcarnitines. 
Following these observations at baseline, we studied the effects of a weight loss intervention on 
acylcarnitines and insulin resistance. Effects of a weight loss intervention on acylcarnitine 
profiles have been described in only two studies, both of which studied lean subjects (27, 28). 
Redman et al compared caloric restriction with and without exercise in non-obese men and 
women, and showed no changes in acylcarnitines in the former group, but increased 
acylcarnitines in the latter, accompanied by a greater improvement in insulin sensitivity 
analogous to our study (28). Here, caloric restriction combined with exercise possibly improves 
the coupling of FAO and TCA flux, preventing acylcarnitines from accumulating. Falk-Petersen et 
al demonstrated in lean sedentary insulin resistant offspring of parents with type 2 diabetes 
(27) that plasma acylcarnitine levels do not change after a 9 week hypocaloric diet, despite 
weight reduction and improved insulin sensitivity. In this case, the unchanged plasma 
acylcarnitines contrast with our results. These subjects were different from ours with respect to 
both body composition and insulin sensitivity. Whether differences in mitochondrial lipid flux 
handling or lipolysis explain the differential effects of the diet on plasma acylcarnitines remains 
elusive. Also, in these particular subjects, the initial insulin resistance may have been a result of 
increased intramyocellular lipids (IMCL) rather than acylcarnitines. Finally, the genetic 
susceptibility of insulin resistant offspring potentially blurs the etiological mechanism of insulin 
resistance (29). For both studies, it should be emphasized that plasma acylcarnitines do not 
reliably reflect individual tissue metabolite levels as we have shown recently (26, 30).  
Although we did not find a convincing correlation at baseline between plasma acylcarnitine 
levels and HOMA-IR, changes over time show that the clear improvement in insulin sensitivity 
was accompanied by a significant increase in acylcarnitine levels. Despite this improvement in 
insulin sensitivity, carbohydrate oxidation rates decreased, probably reflecting the hypocaloric 
  
state which causes an increase in FAO. Additionally the diet-induced lipolysis generates NEFA 
that can directly inhibit carbohydrate oxidation as well. 
The changes in individual chain lengths of acylcarnitines are important because they reveal 
some insight on physiological mechanisms in acylcarnitine metabolism during weight loss. 
Carnitine availability depends on dietary intake and endogenous synthesis. Both carnitine 
uptake via OCTN2 and carnitine synthesis are regulated by PPAR-alpha and are stimulated 
under hypocaloric conditions (17). The absence of increased free carnitine after 28 days of 
intervention may reflect increased esterification to fatty acids and efflux of toxic lipid 
metabolites. This effect was probably lessened after 84 days when weight loss declined and free 
carnitine levels increased. Indeed, the increase in lipid derived acylcarnitines, including C2-
carnitine, was most pronounced after the first 4 weeks. Here the hypocaloric condition and 
subsequent weight loss could cause an improvement of CrAT activity with increased production 
of C2-carnitine, and long chain acylcarnitines that are released from the mitochondria and into 
the plasma compartment (31). When this diet induced CrAT activity declines again over time, 
more free carnitine is released which explains the delay in this increase of free carnitine levels. 
These changes over time were not seen for the amino acid derived acylcarnitines, which shows 
that under hypocaloric conditions lean body mass is more protected than fat mass (32). 
Overall, acylcarnitines increased and insulin sensitivity improved in our study and so our results 
dissociate insulin sensitivity from plasma acylcarnitines. We speculate that the elevated 
acylcarnitine levels on day 28 and day 84 may reflect lipolysis, due to the caloric deficit of the 
weight loss interventions as detailed above. Additionally it could reflect higher rates of FAO and 
CRAT activity, although we could not confirm this with measurements of whole body lipid 
oxidation or acylcarnitines in tissue.  
The effects on both acylcarnitine levels and the clinical parameters, such as weight loss, were 
greatest at 28 days and were weaker at 84 days. It is often seen in weight loss studies that the 
initial effects outweigh the later effects, which may not only be due to changes in treatment 
compliance over time (33-35). Under hypocaloric conditions, whole body energy expenditure 
  
decreases hampering further weight loss once a lower body weight is attained (36-38). The 
increase in acylcarnitines over time also showed a relation with weight loss. Here, a stronger 
decrease in total and lean body weight correlated with higher C4-OH-, C16- and C18:1- 
acylcarnitine levels.  
Although we have analysed and reported on whole group changes over time because of the 
limited number of subjects, the weight loss intervention consisted of three arms (diet, 
sibutramine and exercise) (11). We performed mainly within-group analyses because of the 
primary interest in changes in acylcarnitines over time. However, the different interventions are 
intriguing and reveal subtle, but clear effects on clinical parameters, and acylcarnitine 
metabolism in particular. Over time the sibutramine group lost the most weight and had the 
highest acylcarnitine levels, in contrast to more modest effects in the other two groups. This may 
confirm the idea that lipolysis, which is apparently greater when weight loss is greater, is 
reflected as higher levels of plasma acylcarnitines. Weight loss in the other two groups was 
comparable, but the rise in acylcarnitines was nearly absent upon weight loss in the exercise 
group. This may be due to more efficient mitochondrial fatty acid oxidation due to exercise (28, 
39, 40), which could reduce the accumulation of acylcarnitines in the plasma compartment. 
Although the different interventions were extremely instructive for our understanding of 
acylcarnitine metabolism, the subgroups do have limitations, as the groups were relatively small, 
the exercise intervention was only modest and the marketing application for sibutramine has 
been withdrawn due to side effects of the drug (41). 
In conclusion, we have found an increase in several acylcarnitine species in association with 
weight loss in obese human subjects, despite improvements in insulin sensitivity. It is likely that 
the level of acylcarnitines in plasma is driven by the rate of lipolysis as well as improved efflux 
from cells, potentially as a result of improved CrAT activity and not by deranged mitochondrial 
FAO. The diet derived acylcarnitines, C16- and C18:1-carnitine, seem the most relevant 
acylcarnitines at baseline and during weight loss. However, the importance of plasma 
  
acylcarnitines as clinical markers for insulin resistance seems negligible and the interpretation 
of changes in these lipid intermediates in relation to clinical status remains challenging. 
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Table 1 Baseline characteristics, clinical parameters and plasma acylcarnitine levels  
 Total Diet Exercise Sibutramine  
Subjects (N) 60 20 21 19  
Age (years) 40 (± 8.6) 41 (± 7) 41 (± 8) 40 (± 11)  
Sex (m/f) 23/37 10/10 7/14 6/13  
Bodyweight (kg) 100.9 (± 12.6) 105.0 (± 12.7) 98.7 (± 11.7) 99.2 (± 13.0)  
BMI (kg/m2) 34.8 (± 2.7) 35.2 (± 2.2) 34.5 (± 3.0) 34.8 (± 2.8)  
Fat mass (kg) 43.8 (± 7.6) 43.0 (± 9.1) 41.4 (± 11.5) 43.2 (± 8.4)  
Lean mass (kg) 52.2 (±10.9) 56.4 (± 11.7) 52.2 (± 10.9) 51.0 (± 9.7)  
EE (kJ/min) 5.2 (± 0.8) 5.4 (± 0.7) 5.2 (± 0.9) 5.1 (± 0.8)  
RER 0.81 (± 0.05) 0.81 (± 0.04) 0.79 (± 0.04) 0.84 (± 0.06)a  
FPG (mmol/L) 5.6 (± 0.5) 5.8 (± 0.5) 5.4 (± 0.3) 5.7 (± 0.6)a  
Insulin (pmol/L) 14.7 (± 10.1) 13.2 (± 11.3) 13.2 (± 6.2) 17.9 (± 11.9)  
HOMA-IR 3.7 (± 2.9) 3.5 (± 3.4) 3.2 (± 1.6) 4.6 (± 3.3)  
NEFA (mmol/L) 0.5163 (±0.18) 0.49 (± 0.16)b 0.50 (± 0.18) 0.56 (± 0.19)a  
Acylcarnitines     Ref values 
C0 (µmol/L) 32.9 (± 7.8) 33.5 (± 7.6) 34.3 (± 6.8) 31 (± 9.1) 22.30 – 54.80 
C2 (µmol/L) 4.86 (± 1.68) 4.55 (± 0.96) 5.06 (± 1.13) 4.96 (± 2.56) 3.40 – 13.00 
C4OH (µmol/L) 0.026 (± 0.021) 0.02 (± 0.012) 0.027 (± 0.012) 0.03 (± 0.031) 0.00 – 0.15 
C10 (µmol/L) 0.18 (±0.11) 0.16 (± 0.10) 0.020 (± 0.13) 0.18 (± 0.08) 0.04 – 0.30 
C14:1 (µmol/L) 0.079 (±0.035) 0.07 (± 0.03) 0.085 (± 0.036) 0.08 (± 0.036) 0.02 – 0.18 
C16 (µmol/L) 0.024 (± 0.012) 0.021 (± 0.008) 0.026 (± 0.014) 0.024 (± 0.011) 0.06 – 0.24 
C18:1 (µmol/L) 0.028 (±0.009) 0.029 (± 0.008) 0.028 (± 0.009) 0.028 (± 0.012) 0.06 – 0.28 
 
BMI, body mass index; EE, energy expenditure; RER, respiratory exchange ratio; FPG, fasting 
plasma glucose; HOMA-IR, homeostatic model assessment of insulin resistance; NEFA, non-
esterified fatty acids. Acylcarnitine reference values were acquired and validated by Laboratory 
Genetic Metabolic Diseases, Academic Medical Center, Amsterdam. Data are represented as 
mean ± standard deviation; a = statistical significant between exercise and sibutramine, b = 
significant between exercise and placebo. 
  
 Table 2 Correlations of plasma NEFA with plasma acylcarnitines 
  Plasma NEFA 
 Spearman ρ p 
C0 0.24 0.07 
C2 0.50 0.00 * 
C4OH  0.40 0.00 * 
C10  0.22 0.11 
C14:1  0.53 0.00 * 
C16  0.60 0.00 * 
C18:1 0.46 0.00 * 
 
Spearman correlation analysis shows a strong correlation of C2-, C4OH-, C14:1-, C16- and C18:1-
carnitine with plasma NEFA at baseline. P-values are shown before Bonferroni correction 
whereas * refers to p-values that remained significant after Bonferroni correction.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
Table 3 Multiple regression analysis of plasma NEFA levels and selected plasma acylcarnitines 
Analysis including C4OH-carnitine Analysis excluding C4OH-carnitine 
 
Unstandardized 
Coefficient B 
p  
Unstandardized 
Coefficient B 
p 
C0 -0.01 0.19 C0 -0.00 0.54 
C2 0.05 0.12 C2 0.01 0.72 
C4OH -3.40 0.08    
C10 -0.39 0.16 C10 -0.25 0.36 
C14:1 2.55 0.04 * C14:1 1.84 0.11 
C16 2.51 0.04 * C16 3.07 0.01 * 
C18:1 -0.13 0.91 C18:1 -0.16 0.89 
 
Multiple regression analysis illustrates that variation in plasma NEFA is driven by C14:1 and 
C16-carnitine. When C4OH-carnitine was omitted (as it predominantly emerges during 
starvation), only C16-carnitine remained significant. 
 
